Absence from work in the 12 months following mild traumatic brain injury in Europe: a CENTER-TBI cohort study
Por:
Jacob L., Castro J, Heslot C, Andelic N, Tenovuo O and Azouvi P
Publicada:
1 nov 2025
Ahead of Print:
1 sep 2025
Resumen:
Background: Most of the prior research on absence from work after a mild traumatic brain injury (mTBI) was of a small sample size and had a limited number of follow-up assessments. Objectives: Therefore, this study investigated the prevalence of absence from work, trajectories, and associated factors in the 12 months following mTBI in Europe. Methods: Data from a European cohort (CENTER-TBI) were used. Absence from work was assessed at 2 weeks, 3 months, 6 months, and 12 months after mTBI. Associated factors included sociodemographic factors, current psychoactive substance use, pre-injury medical history, injury-related factors, medical care, complications, and discharge, and 2-week follow-up questionnaires. Inferential analyses relied on generalized estimating equations. Results: This study included 1080 adults with mTBI who were working at the time of the injury (median [IQR] age, 46.0 [23.0] years; 69 % men). Absence from work decreased from 32 % at 2 weeks to 20 % at 12 months after the injury (P < 0.001). Around 76 % of adults returned to work within the first 3 months, whereas > 43 % of those absent from work at 3 months remained absent at 12 months. The 3 factors with the strongest association with absence from work were admission to hospital wards (OR = 2.57) or intensive care units (OR = 4.76), the presence of a pre-injury psychiatric disorder (OR = 2.55), and older age (OR = 1.61). Conclusions: One-fifth of workers with mTBI were absent from work 12 months after the injury. Early identification of those at particular risk for not returning to work should be a clinical priority.
Filiaciones:
Jacob L.:
Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Cité, Lariboisière-Fernand Widal Hospital, Department of Physical Medicine and Rehabilitation, Paris 75010, France
Inserm, Université Paris Cité, U1153, Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), Paris 75010, France
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, Barcelona 08830, Spain
Castro J:
Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Saclay, Raymond Poincaré Hospital, Department of Physical Medicine and Rehabilitation, Garches 92380, France
Université Paris-Saclay, UVSQ, Inserm, CESP, MOODS research team, Villejuif 94807, France
Heslot C:
Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Cité, Lariboisière-Fernand Widal Hospital, Department of Physical Medicine and Rehabilitation, Paris 75010, France
Sorbonne Université, Paris Brain Institute (ICM), Frontlab, CNRS UMR 7225, INSERM U1127, Paris 75013, France
Andelic N:
Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo 0372, Norway
Tenovuo O:
Turku Brain Injury Centre, Turku University Hospital and University of Turku, Turku FI-20014, Finland
Azouvi P:
Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Saclay, Raymond Poincaré Hospital, Department of Physical Medicine and Rehabilitation, Garches 92380, France
Université Paris-Saclay, UVSQ, Inserm, CESP, MOODS research team, Villejuif 94807, France
Green Submitted, hybrid
|